je.st
news
Tag: merck
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA (pembrolizumab) in Solid Tumors
2015-04-20 14:00:00| Merck.com - Product News
Dateline City: MALVERN, Pa. & KENILWORTH, N.J. MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orTetraLogic Investor Relations:Pete A. Meyers, 610-889-9900, x103pete.meyers@tlog.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
combination
solid
evaluation
Studies: Merck drug Keytruda effective against 3 cancers
2015-04-19 20:16:47| Biotech - Topix.net
One of the hot new cancer immunotherapy drugs, Merck & Co.' s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer Research conference in Philadelphia.
Tags: effective
studies
drug
cancers
Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2015-04-19 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
application
license
cell
Merck aims to quickly repay up to $5 billion in loans - CFO in Boersen-Zeitung
2015-04-18 20:49:36| Chemicals - Topix.net
Germany's Merck aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich , its finance chief told daily Boersen-Zeitung. "We want to reduce the loans very aggressively within two to three years to stabilise our credit rating and to regain financial leeway for further acquisitions," Marcus Kuhnert told the paper in an interview published on Saturday.
Tags: in
quickly
loans
billion
Merck appoints new leader for Sigma-Aldrich business
2015-04-15 16:21:54| Chemicals - Topix.net
Merck has appointed Udit Batra to lead the company's life science business unit upon the completion of its $17 billion acquisition of Sigma-Aldrich . Batra, who is the current president and CEO of Merck Millipore, will lead the unit that will combine the business of Merck Millipore and Sigma-Aldrich, European Pharmaceutical Review reports.
Tags: business
leader
merck
appoints
Sites : [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] next »